Ipamorelin releases a clean growth-hormone pulse — and its human record is thinner than its reputation.

Start here

Ipamorelin is a small lab-made peptide — a chain of five amino acids — that tells the pituitary gland (a pea-sized gland under the brain) to release a short burst of growth hormone. What sets it apart from older peptides in its family is how clean that burst is: in the founding study it raised growth hormone strongly but left stress hormones like cortisol untouched ^[1]. That selectivity is the whole reason researchers got interested.

Here is the honest state of the evidence. Most of what we know comes from rats, swine, and a single small human study of how the drug moves through the body ^[2]. The one human trial that tested whether it actually helps anyone — speeding up bowel recovery after surgery — did not work ^[3]. Ipamorelin has never been approved as a medicine anywhere, and in 2024 U.S. regulators tightened pharmacy access to it. What people report from real-world use — including the downsides — is on the effects page. Nothing here is legal or medical advice, and nothing is sold.

What the ipamorelin record actually shows

The defining finding is selectivity. In the 1998 characterization that named it, ipamorelin (sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2) released growth hormone as potently as the older peptide GHRP-6 — an ED50 of 2.3 nmol/kg in conscious swine versus 3.9 nmol/kg for GHRP-6 — yet did not raise ACTH or cortisol above baseline even at doses more than 200-fold above its growth-hormone ED50 ^[1]. No GHRP before it had drawn that clean a line.

The mechanism is worth stating plainly. Ipamorelin is a ghrelin mimetic: it switches on the GHS-R1a receptor (the same receptor the hunger hormone ghrelin uses) on the pituitary's growth-hormone cells, and that triggers a single discrete pulse ^[1]. Because it works through a different door than growth-hormone-releasing hormone (GHRH), researchers pair it with GHRH analogs — which is the logic behind the popular CJC-1295 combination ^[7].

In humans, the one clean dataset is pharmacokinetic: a terminal half-life of about 2 hours, with the growth-hormone response peaking near 40 minutes after a dose ^[2]. That is the bright, confirmed end of the chart.

Where the chart goes faint

Reputation has outrun evidence here. Clinic and online promotion frames ipamorelin for anti-aging, fat loss, and muscle gain, but those claims rest on mechanism and short rodent studies — not on controlled human outcome trials.

The one human efficacy trial that exists is negative. In a Phase 2 randomized controlled trial of postoperative ileus (NCT00672074, 114 bowel-resection patients), ipamorelin missed its primary endpoint: median time to a first tolerated meal was 25.3 hours versus 32.6 hours on placebo (p=0.15) ^[3]. No Phase 3 trial followed, and there is no approved indication.

Long-term safety in humans is uncharacterized. A 28-day study of a different GHS-R1a agonist found dose-dependent heart-muscle damage in rats — a class-level signal, not an ipamorelin finding, but the reason chronic dosing deserves scrutiny ^[6]. The full Ipamorelin research page walks through each study; what people report and who should be careful is on the Ipamorelin effects page.

Reading the 'legal' question honestly

The domain name says 'legal,' so the framing here is regulatory due diligence — not legal advice, and not a verdict on any person's situation. The facts: ipamorelin is not approved by the FDA, EMA, or any regulator as a drug for any use ^[3]. In 2024 the FDA removed ipamorelin acetate from Category 2 of the interim Section 503A bulk-substances list and reviewed it at the October 29, 2024 Pharmacy Compounding Advisory Committee meeting, narrowing the path for compounding pharmacies to supply it. Separately, ipamorelin and other growth hormone secretagogues are prohibited in sport at all times under the World Anti-Doping Agency list (category S2), and accredited laboratories can detect them in urine.

Those are status facts, drawn from the public record. Anyone weighing a real-world decision should read the Ipamorelin references and consult a qualified professional; this site only summarizes published science.